Viking Therapeutics Stock Surges on Clinical Success and Acquisition Buzz
Published on 01/15/2026 at 06:23 | Redaktion boerse-global.de
Shares of Viking Therapeutics, a clinical-stage biotechnology firm, experienced a significant rally, closing at $34.34 with a gain of approximately 11.44%. The move reflects renewed investor enthusiasm driven by compelling clinical trial results and heightened speculation regarding a potential acquisition by larger pharmaceutical companies.
The primary catalyst for the recent share price appreciation is positive data from the company’s drug candidate, VK2735. Results from the Phase 2 VENTURE study demonstrated that participants achieved an average weight reduction of 14.7%. This outcome positions VK2735 as a competitive contender in the lucrative obesity treatment market, currently dominated by GLP-1 therapies.
The publication of these findings in the peer-reviewed journal Obesity is viewed Read more...
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
